K36 Therapeutics is a biopharmaceutical company focused on developing targeted therapies for multiple myeloma patients. Their lead candidate, KTX-1001, is a selective inhibitor of the histone methyltransferase (HMT) MMSET, which is overexpressed in some multiple myeloma patients due to a specific genetic translocation.

K36 Therapeutics

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Aug 26, 2024 3:42 AM	563957bf
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	73b0010e
crunchbase profile	general
li profile	general
translate crunchbase fundingrounds	general
peers	general	Aug 26, 2024 3:42 AM	caf61b64
news basic	general	Aug 26, 2024 3:42 AM	0c3ef101
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:K36TX

K36 Therapeutics